UNLIMITED TURBO LONG - INMODE Stock

Certificat

DE000PC80BC5

Market Closed - Boerse Frankfurt Warrants 15:50:27 2024-06-07 EDT
3.03 EUR -0.98% Intraday chart for UNLIMITED TURBO LONG - INMODE
Current month-20.21%
1 month-9.79%
Date Price Change
24-06-07 3.04 -0.65%
24-06-06 3.06 -10.53%
24-06-05 3.42 -2.29%
24-06-04 3.5 -7.65%
24-06-03 3.79 -0.52%

Real-time Boerse Frankfurt Warrants

Last update June 07, 2024 at 03:50 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying INMODE LTD.
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC80BC
ISINDE000PC80BC5
Date issued 2024-04-29
Strike 16.16 $
Maturity Unlimited
Parity 1 : 1
Emission price 1.37
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.23
Lowest since issue 1.83

Company Profile

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Sector
-
More about the company

Ratings for InMode Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: InMode Ltd.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
18.25 USD
Average target price
25.6 USD
Spread / Average Target
+40.27%
Consensus